Filter
Bimekizumab Treatment in Psoriatic Arthritis Resulted in Sustained Efficacy Assessed Using Composite Outcome Measures to 3 Years
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Phase 2b/3 Results
Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial